Watch Demo

Biologics Contract Manufacturing Market Research Report by Product, Platform, Therapeutic Area, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

Biologics Contract Manufacturing Market Research Report by Product, Platform, Therapeutic Area, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030
  • Publish Date:January 2023

  • Number of Pages:153

  • Report ID:6388212

  • Format:PDF

  • Publisher:360iResearch

$ 3949

Summary

Biologics Contract Manufacturing Market Research Report by Product (Biosimilar, Insulin, and Interferons), Platform, Therapeutic Area, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

The United States Biologics Contract Manufacturing Market size was estimated at USD 4,098.78 million in 2022 and expected to reach USD 4,704.88 million in 2023, projecting growth at a CAGR of 16.31% to reach USD 13,735.41 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States Biologics Contract Manufacturing Market.

Cumulative Impact of Russia-Ukraine Conflict:

We continuously monitor and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States Biologics Contract Manufacturing Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States Biologics Contract Manufacturing Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States Biologics Contract Manufacturing Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States Biologics Contract Manufacturing Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the market is studied across Biosimilar, Insulin, Interferons, Monoclonal Antibodies, Recombinant Hormones, and Vaccines.

Based on Platform, the market is studied across Mammalian and Microbial.

Based on Therapeutic Area, the market is studied across Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Neurology, Oncology, Ophthalmology, and Respiratory Disorders.

Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States Biologics Contract Manufacturing Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States Biologics Contract Manufacturing Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States Biologics Contract Manufacturing Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States Biologics Contract Manufacturing Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Biologics Contract Manufacturing Market, including AbbVie, Inc., Abzena Ltd., AGC Biologics, Ajinomoto Bio-Pharma Services, Avid Bioservices, Inc., Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions, Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, JSR Life Sciences, LLC by JSR Group, Lonza Group Ltd., ProBioGen AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, Thermo Fisher Scientific, Inc., Toyobo Co. Ltd., and WuXi Biologics Co., Ltd..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Biologics Contract Manufacturing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Biologics Contract Manufacturing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Biologics Contract Manufacturing Market?
4. What is the competitive strategic window for opportunities in the United States Biologics Contract Manufacturing Market?
5. What are the technology trends and regulatory frameworks in the United States Biologics Contract Manufacturing Market?
6. What is the market share of the leading vendors in the United States Biologics Contract Manufacturing Market?
7. What modes and strategic moves are considered suitable for entering the United States Biologics Contract Manufacturing Market?

Table of contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Innovation and robust vaccine and other biologics pipeline in the U.S
5.1.1.2. Cost and time-saving benefits offered by contract services
5.1.2. Restraints
5.1.2.1. High expenses associated with the logistics and storage
5.1.3. Opportunities
5.1.3.1. High consolidation activities by biologics contract manufacturing players
5.1.3.2. Introduction of single-use bioprocessing equipment & solutions in CMOs
5.1.4. Challenges
5.1.4.1. Concerns about infringement of intellectual property and patents
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Biologics Contract Manufacturing Market, by Product
6.1. Introduction
6.2. Biosimilar
6.3. Insulin
6.4. Interferons
6.5. Monoclonal Antibodies
6.6. Recombinant Hormones
6.7. Vaccines

7. Biologics Contract Manufacturing Market, by Platform
7.1. Introduction
7.2. Mammalian
7.3. Microbial

8. Biologics Contract Manufacturing Market, by Therapeutic Area
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cardiovascular Diseases
8.4. Infectious Diseases
8.5. Metabolic Diseases
8.6. Neurology
8.7. Oncology
8.8. Ophthalmology
8.9. Respiratory Disorders

9. California Biologics Contract Manufacturing Market
9.1. Introduction

10. Florida Biologics Contract Manufacturing Market
10.1. Introduction

11. Illinois Biologics Contract Manufacturing Market
11.1. Introduction

12. New York Biologics Contract Manufacturing Market
12.1. Introduction

13. Ohio Biologics Contract Manufacturing Market
13.1. Introduction

14. Pennsylvania Biologics Contract Manufacturing Market
14.1. Introduction

15. Texas Biologics Contract Manufacturing Market
15.1. Introduction

16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis, By Key Player
16.3. Market Share Analysis, By Key Player
16.4. Product Portfolio Analysis, By Key Player
16.5. Competitive Scenario
16.5.1. Merger & Acquisition
16.5.2. Agreement, Collaboration, & Partnership
16.5.3. New Product Launch & Enhancement
16.5.4. Investment & Funding
16.5.5. Award, Recognition, & Expansion

17. Company Usability Profiles
17.1. AbbVie, Inc.
17.2. Abzena Ltd.
17.3. AGC Biologics
17.4. Ajinomoto Bio-Pharma Services
17.5. Avid Bioservices, Inc.
17.6. Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
17.7. Cambrex Corporation
17.8. Catalent, Inc.
17.9. Emergent BioSolutions, Inc.
17.10. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
17.11. JSR Life Sciences, LLC by JSR Group
17.12. Lonza Group Ltd.
17.13. ProBioGen AG
17.14. Recipharm AB
17.15. Rentschler Biopharma SE
17.16. Samsung Biologics
17.17. Thermo Fisher Scientific, Inc.
17.18. Toyobo Co. Ltd.
17.19. WuXi Biologics Co., Ltd.

18. Appendix
18.1. Discussion Guide
18.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2022 VS 2030
FIGURE 3. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 5. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 7. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET DYNAMICS
FIGURE 8. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET PORTER'S FIVE FORCES ANALYSIS
FIGURE 9. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
FIGURE 10. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET COMPETITIVE STRATEGIC WINDOW, BY PRODUCT, 2030
FIGURE 12. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
FIGURE 13. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
FIGURE 14. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
FIGURE 15. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
FIGURE 16. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT HORMONES, 2018-2030 (USD MILLION)
FIGURE 17. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
FIGURE 18. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2022 VS 2030 (%)
FIGURE 19. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET COMPETITIVE STRATEGIC WINDOW, BY PLATFORM, 2030
FIGURE 21. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
FIGURE 22. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
FIGURE 23. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2022 VS 2030 (%)
FIGURE 24. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET COMPETITIVE STRATEGIC WINDOW, BY THERAPEUTIC AREA, 2030
FIGURE 26. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
FIGURE 27. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
FIGURE 28. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
FIGURE 29. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY METABOLIC DISEASES, 2018-2030 (USD MILLION)
FIGURE 30. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
FIGURE 31. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
FIGURE 32. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
FIGURE 33. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
FIGURE 34. CALIFORNIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 35. FLORIDA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 36. ILLINOIS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 37. NEW YORK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 38. OHIO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 39. PENNSYLVANIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 40. TEXAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 41. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 42. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 43. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022

List of Tables

TABLE 1. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 5. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 6. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR, 2018-2030 (USD MILLION)
TABLE 7. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR, BY STATE, 2018-2030 (USD MILLION)
TABLE 8. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
TABLE 9. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INSULIN, BY STATE, 2018-2030 (USD MILLION)
TABLE 10. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 11. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INTERFERONS, BY STATE, 2018-2030 (USD MILLION)
TABLE 12. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 13. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY STATE, 2018-2030 (USD MILLION)
TABLE 14. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT HORMONES, 2018-2030 (USD MILLION)
TABLE 15. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT HORMONES, BY STATE, 2018-2030 (USD MILLION)
TABLE 16. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 17. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, BY STATE, 2018-2030 (USD MILLION)
TABLE 18. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
TABLE 19. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 20. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY STATE, 2018-2030 (USD MILLION)
TABLE 21. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 22. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MICROBIAL, BY STATE, 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISEASES, BY STATE, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY STATE, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY STATE, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY METABOLIC DISEASES, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY METABOLIC DISEASES, BY STATE, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY STATE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY STATE, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESPIRATORY DISORDERS, BY STATE, 2018-2030 (USD MILLION)
TABLE 40. CALIFORNIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 41. CALIFORNIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 42. CALIFORNIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
TABLE 43. CALIFORNIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 44. FLORIDA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 45. FLORIDA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 46. FLORIDA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
TABLE 47. FLORIDA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 48. ILLINOIS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 49. ILLINOIS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 50. ILLINOIS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
TABLE 51. ILLINOIS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 52. NEW YORK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 53. NEW YORK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 54. NEW YORK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
TABLE 55. NEW YORK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 56. OHIO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 57. OHIO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 58. OHIO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
TABLE 59. OHIO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 60. PENNSYLVANIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 61. PENNSYLVANIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 62. PENNSYLVANIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
TABLE 63. PENNSYLVANIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 64. TEXAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 65. TEXAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 66. TEXAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2018-2030 (USD MILLION)
TABLE 67. TEXAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 69. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 70. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 71. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET RANKING, BY KEY PLAYER, 2022
TABLE 72. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2022
TABLE 73. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 74. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET MERGER & ACQUISITION
TABLE 75. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 76. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 77. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET INVESTMENT & FUNDING
TABLE 78. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 79. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET: LICENSE & PRICING

Companies Mentioned

AbbVie, Inc.
Abzena Ltd.
AGC Biologics
Ajinomoto Bio-Pharma Services
Avid Bioservices, Inc.
Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
Cambrex Corporation
Catalent, Inc.
Emergent BioSolutions, Inc.
FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
JSR Life Sciences, LLC by JSR Group
Lonza Group Ltd.
ProBioGen AG
Recipharm AB
Rentschler Biopharma SE
Samsung Biologics
Thermo Fisher Scientific, Inc.
Toyobo Co. Ltd.
WuXi Biologics Co., Ltd.

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.